eligibility_summary
Eligibility: Advanced/metastatic gastric, GEJ, or esophageal adenocarcinoma amenable to intratumoral injection (≥1 cm), PD‑L1 CPS ≥1, HER2‑negative. Exclude: recent investigational/anti‑cancer therapy or unresolved AEs, active autoimmune disease, immunodeficiency or systemic steroids, CNS mets, other active malignancy (except prostate on ADT), live vaccine, HBV/HCV/HIV, pneumonitis/ILD, infection, noncompliance, severe mAb allergy, major surgery, allogeneic transplant, uncontrolled illness, pregnancy/breastfeeding, planning conception.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm study in immunotherapy‑refractory, PD‑L1+ (CPS ≥1), HER2– esophagogastric adenocarcinoma. Interventions: 1) OBP‑301 (suratadenoturev/Telomelysin) – an intratumoral, engineered oncolytic adenovirus (drug type: oncolytic virotherapy) using the hTERT promoter to drive selective replication in telomerase‑positive cancer cells, inducing oncolysis and immunogenic tumor antigen release. 2) Pembrolizumab – an anti‑PD‑1 IgG4 monoclonal antibody (drug type: immune checkpoint inhibitor) that blocks PD‑1 to reinvigorate exhausted T cells. Targets/pathways: telomerase (hTERT)–expressing tumor cells, PD‑1/PD‑L1 immune checkpoint on T cells/tumor/immune cells, enhancing dendritic priming and CD8+ T‑cell–mediated killing to overcome checkpoint resistance.